Acetaminophen
- Generic Name
- Acetaminophen
- Brand Names
- Acephen, Acetadryl, Allzital, Apadaz, Arthriten Inflammatory Pain, Bupap, Butapap, Cetafen, Children's Silapap, Coricidin Hbp Cold & Flu, Darvocet-N, Dayquil Sinex, Diphen, Dolofin, Dologen, Dologesic Reformulated Jun 2016, Duralgina, Dvorah, Endocet, Esgic, Exaprin, Excedrin, Excedrin PM Triple Action, Excedrin Tension Headache, Feverall, Fioricet, Fioricet With Codeine, Goody's Back & Body Pain Relief, Goody's Body Pain, Goody's Extra Strength, Goody's Headache Relief Shot, Goody's PM, Hycet, Legatrin PM, Little Fevers, Lorcet, Lortab, Mapap, Mersyndol, Midol Complete, Midol Cramps & Bodyaches, Nalocet, Norco, Orbivan, Pamprin Max Formula, Pamprin Multi-symptom, Panadol, Pediacare Children's Fever Reducer Pain Reliever, Percocet, Percogesic Reformulated Jan 2011, Pharbetol, Premsyn Pms, Prolate, Rivacocet, Robaxacet, Robaxacet-8, Roxicet, Sudafed PE Sinus Headache, Tactinal, Tencon, Trezix, Triatec, Triatec-30, Triatec-8, Tylenol, Tylenol PM, Tylenol With Codeine, Ultracet, Vanatol, Vanatol S, Vanquish, Xodol, Xolox, Zamicet, Zflex, Zydone
- Drug Type
- Small Molecule
- Chemical Formula
- C8H9NO2
- CAS Number
- 103-90-2
- Unique Ingredient Identifier
- 362O9ITL9D
- Background
Acetaminophen (paracetamol), also commonly known as Tylenol, is the most commonly taken analgesic worldwide and is recommended as first-line therapy in pain conditions by the World Health Organization (WHO). It is also used for its antipyretic effects, helping to reduce fever. This drug was initially approved by the U.S. FDA in 1951 and is available in a var...
- Indication
In general, acetaminophen is used for the treatment of mild to moderate pain and reduction of fever. It is available over the counter in various forms, the most common being oral forms.
...
- Associated Conditions
- Acute Gouty Arthritis, Acute Musculoskeletal Pain, Allergic Reaction, Allergy to Tree Pollen, Ankylosing Spondylitis (AS), Chills, Cold, Common Cold, Cough, Cough caused by Common Cold, Coughing caused by Flu caused by Influenza, Dyskinesia of the Biliary Tract, Dyskinesia of the Urinary Tract, Febrile Convulsions, Febrile Illness Acute, Fever, Fibromyalgia, Flu caused by Influenza, Headache, Joint dislocations, Menstrual Distress (Dysmenorrhea), Mild pain, Muscle Inflammation, Muscle Injuries, Muscle Spasms, Musculoskeletal Pain, Myalgia, Nasal Congestion, Neuropathic Pain, Osteoarthritis (OA), Pain, Postoperative pain, Premenstrual cramps, Rheumatoid Arthritis, Rhinopharyngitis, Rhinorrhoea, Severe Pain, Sinusitis, Spasms, Spastic Pain of the Gastrointestinal Tract, Sprains, Symptoms Cold, Tension Headache, Toothache, Upper Respiratory Tract Infection, Whiplash Syndrome, Acute Torticollis, Articular inflammation, Cold or flu syndrome, Mild to moderate pain, Minor aches and pains, Minor pain, Moderate Pain, Moderate to severe pain
- Associated Therapies
- Airway secretion clearance therapy, Anti-spasmodics, Bronchodilation
Savara Initiates Rolling Submission of a Biologics License Application (BLA) to the U.S.
Savara Inc. initiated a rolling BLA submission to the FDA for MOLBREEVI, a potential treatment for aPAP, a rare lung disease. MOLBREEVI has Fast Track, Breakthrough Therapy, and Orphan Drug designations. The company expects to complete the BLA submission by end of 1Q 2025.
Savara's MOLBREEVI Advances Toward First-Ever aPAP Treatment with FDA Rolling BLA
Savara Inc. initiated a rolling BLA submission to the FDA for MOLBREEVI, targeting aPAP treatment, expecting completion by Q1 2025. MOLBREEVI has Fast Track, Breakthrough Therapy, and Orphan Drug designations, with positive Phase 3 IMPALA-2 trial results. If approved, it could be the first aPAP treatment in the U.S. and Europe.
U.S. Teen Drug, Alcohol Use Remains at Low Levels
U.S. teen drug and alcohol use remains low post-pandemic, according to NIDA's Monitoring the Future survey. Alcohol, vaping, cannabis, and illicit drug use among 8th, 10th, and 12th graders either declined or remained stable. The trend marks the lowest rates of substance use in decades.
Reported Use of Most Drugs Among Adolescents Remained Low in 2024
Substance use among adolescents remained low in 2024, continuing a trend since the COVID-19 pandemic. The Monitoring the Future Survey, funded by NIH, found stable or declining use of most drugs, with alcohol, nicotine vaping, and cannabis seeing the most reported use. Factors contributing to this trend are under investigation to inform future interventions.
Tuva Health Launches with $5M to Clean Messy Healthcare Data
Tuva Health, an open-source healthcare data platform, launched with $5M seed funding to help payers, providers, and pharma companies normalize and analyze claims and EHR data. The platform, created by a community of 1,500 healthcare data professionals, aims to improve data interoperability and analytics in healthcare.
Cumberland Stock Soars 90% After FDA Approval for Acetadote Dosing Change
Cumberland Pharmaceuticals' stock surged over 90% today, up 101% in a month, driven by FDA approval of a supplementary New Drug Application for Acetadote®, simplifying dose schedules to improve safety and efficacy in treating liver damage from acetaminophen. Hospitals have adopted the strategy to reduce medication errors and severe non-allergic anaphylactoid responses. The FDA's Orphan Drug and Rare Pediatric Disease Designations for its Duchenne muscular dystrophy medication have also boosted investor confidence.
IV Form of NAC Receives FDA sNDA to Prevent, Lessen Liver Injury After Ingesting Toxic
The FDA approved a simplified dosing regimen for N-acetylcysteine (NAC) to prevent liver injury from acetaminophen overdose, reducing medication errors and non-allergic anaphylactoid reactions (NAARs). Studies show the 2-bag regimen shortens delays and reduces NAARs compared to the 3-bag regimen, improving patient outcomes.
FDA Approves Simplified Dosing For Cumberland's Acetadote
The FDA approved a simplified dosing regimen for Cumberland Pharmaceuticals Inc.'s Acetadote, aiming to prevent liver injury from acetaminophen poisoning by combining the first two bags of the standard regimen into a single, slower infusion to reduce medication errors and non-allergic anaphylactoid reactions.
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath